Considering the important predictive value of HHLA2/PD-L1 co-expression for both PFS and OS, and the significant correlation between HHLA2/PD-L1 co-expression and high density of TILs in ccRCC, we classified the patients into six types, based on TILs and HHLA2/PD-L1 co-expression, to provide rationale for immunotherapy. The gene discussed is HHLA2; the disease is nonpapillary renal cell carcinoma.